Years and Older with Shingrix
SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.
SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).
In the pivotal clinical trials, the most common solicited adverse reactions observed were pain, redness, and swelling at the injection site, myalgia, fatigue, headache, shivering, fever, and gastrointestinal symptoms.
- *Data from the phase 3 ZOE-50 (≥50 years of age) trial and pooled data in individuals ≥70 years of age from the phase 3 ZOE-50 and ZOE-70 trials in subjects who received 2 doses of SHINGRIX (N=7344 and 8250, respectively) or placebo (N=7415 and 8346, respectively) and did not develop a confirmed case of herpes zoster within 1 month after the second dose. See study designs on Efficacy page for more details.1
The page links below may be of special interest to you and your team.
Thank you for doing your part to help prevent shingles in your appropriate patients.
See how you and your staff can reconstitute SHINGRIX in four steps.
CDC states that SHINGRIX is recommended for the prevention of herpes zoster and related complications for immunocompetent adults aged ≥50 years.2
CDC=Centers for Disease Control and Prevention.